Clinical trials: Hematological Disease
Acute Myeloid Leukemia With FLT3/ITD Mutation, Recurrent Acute Myeloid Leukemia
Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
This phase Ib/II trial studies the side effects and best dose of venetoclax in combination with quizartinib and how well they work in treating patients with acute myeloid leukemia that has come back or does not respond to…
- Conditions
- Acute Myeloid Leukemia With FLT3/ITD Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Leukemia
- Trial name
- NCT03735875
- Testing
- Quizartinib, Venetoclax
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemias, Acute Myeloid Leukemia (AML)
Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia
This study is designed to determine the safety, maximum tolerated dose,dose limiting toxicity of Terameprocol(EM-1421)and determine the pharmacokinetics (clearance from the blood)of Terameprocol(EM-1421)given as intravenous…
- Conditions
- Leukemias, Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Adult T Cell Leukemia (ATL)
- Trial name
- NCT00664677
- Testing
- Terameprocol (EM-1421)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Erimos Pharmaceuticals
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients
The purpose of the study is to investigate whether the combination of rituximab and high dose methylprednisolone can be given together, can reduce the amount of cancer cells that are present prior to starting venetoclax, and…
- Trial name
- NCT04981912
- Testing
- HDMP + rituximab as a means of debulking prior to initiating venetoclax.
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of California, San Diego
Leukemia, Medulloblastoma
Immuno 1: Immune Reconstitution Following Conventional or High-Dose Chemotherapy With Stem Cell Transplant
The purpose of this study is to conduct an analysis of the influences of 1. conventional chemotherapy 2. high-dose chemotherapy followed by autologous stem cell transplant 3.
- Trial name
- NCT00231712
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Julius-Maximilians University
Recurrent Plasma Cell Myeloma
Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
This phase II trial studies how well daratumumab, pomalidomide, and dexamethasone work in treating patients with multiple myeloma that has come back (relapsed).
- Trial name
- NCT03841565
- Testing
- Daratumumab, Dexamethasone, Pomalidomide
- Where
- 5 sites in United States
- Sponsor
- Academic and Community Cancer Research United
Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to assess the safety and efficacy of ponatinib in Japanese patients with chronic myeloid leukemia (CML) who have experienced failure of dasatinib or nilotinib or with Ph+ acute lymphoblastic leukemia…
- Trial name
- NCT01667133
- Testing
- ponatinib - Phase 1, ponatinib - Phase 2
- Where
- 11 sites in Japan
- Volunteers
- 35 people
- Sponsor
- Ariad Pharmaceuticals
Multiple Myeloma
Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
This is a pilot feasibility trial among older adults (≥60y) scheduled to undergo Autologous Stem Cell transplantation at UAB. Participants will be randomized into either a prehabilitation program or an attention control group…
- Trial name
- NCT05642884
- Testing
- Multi-modal Exercise Regimen, Dietary Guidelines
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Noha Mohamed Sharafeldin
Sickle Cell Disease, Pain
Nitric Oxide and Sickle Cell Pain
Background: Sickle cell disease often causes crises, with episodes of pain. Many people with sickle cell disease also have pain between crises. Inflammation is an important part of sickle cell pain.
- Trial name
- NCT01393847
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- National Institute of Nursing Research (NINR)
Leukemia
Study to Predict Risk of Relapse in Bone Marrow Cell Samples From Younger Patients With Acute Myeloid Leukemia
RATIONALE: A screening test, such as My Profile Pediatric Assay, may help doctors predict a patient's risk of relapse and plan better treatment for acute myeloid leukemia.
- Trial name
- NCT01438138
- Testing
- diagnostic laboratory biomarker analysis
- Volunteers
- 98 people
- Sponsor
- Children's Oncology Group
Breast Neoplasms, Fever
A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer
This is a prospective, randomized Phase III trial of FLAC chemotherapy with GM-CSF versus PIXY321 in advanced breast cancer. The primary endpoints of this study will be the duration of thrombocytopenia and the time to recovery of…
- Conditions
- Breast Neoplasms, Fever, Hematologic Diseases, Neutropenia
- Trial name
- NCT00001338
- Testing
- FLAC chemotherapy with GM-CSF
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma
The purpose of this study is to evaluate the safety and effect on the body of Tabalumab (LY2127399) in combination with bortezomib and dexamethasone in Japanese participants with relapsed or refractory multiple myeloma (MM).
- Trial name
- NCT01556438
- Testing
- Tabalumab, Bortezomib IV, Bortezomib SC
- Where
- 5 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Eli Lilly and Company
Thrombocytopaenia
SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy
SB497115 is an oral agent which activates the thrombopoietin receptor and increases platelet counts in healthy volunteers. This study is examining several different doses of SB497115 versus placebo as treatment for patients with…
- Trial name
- NCT00102726
- Testing
- SB497115
- Where
- 95 sites in United States, Argentina and 17 more
- Volunteers
- 183 people
- Sponsor
- GlaxoSmithKline
Ph-Like, Acute Lymphoblastic Leukemia
ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL
This open-label, non-randomized, phase II exploratory study aims to evaluate the efficacy and safety of combining pathway-specific tyrosine kinase inhibitors with chemotherapy and venetoclax in patients with newly diagnosed…
- Trial name
- NCT07454226
- Testing
- Olverembatinib, Gecacitinib, Venetoclax
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Cancer, Chronic Lymphocytic Leukemia
AMG 319 Lymphoid Malignancy FIH
This is a multi-center, phase 1, open-label first-in-human study of AMG 319 in subjects with relapsed or refractory lymphoid malignancies. This study consists of two parts.
- Conditions
- Cancer, Chronic Lymphocytic Leukemia, Diffuse Large Cell Lymphoma, Hematologic Malignancies
- Trial name
- NCT01300026
- Testing
- AMG 319
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Amgen
T-cell Leukemia, T-cell Lymphoma
Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies
The prognosis of patients with relapsed and/or refractory T-cell hematologic malignancies is poor due to lacking sufficient treatment.Anti-CD(cluster of differentiation antigen)19 CAR(chimeric antigen receptor)-T cell therapies…
- Trial name
- NCT04264078
- Testing
- CD7 UCAR-T cells, Fludarabine, Cytoxan
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Xinqiao Hospital of Chongqing
Pseudoxanthoma Elasticum
PPI Supplementation to Fight ECtopIc Calcification in PXE
Pseudoxanthoma elasticum (PXE) is a rare inherited metabolic disorder (OMIM 264800, frequency 1/25000) characterized by progressive ectopic calcification of connective tissues.
- Trial name
- PROPHECI-PPI (NCT04868578)
- Testing
- study treatment PPI
- Where
- 2 sites in France
- Volunteers
- 99 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Heart Failure, Left Sided, Anemia, Iron Deficiency
ORal IrON Supplementation With Ferric Maltol in Patients With Heart Failure Carrying Left Ventricular Assist Devices
This is a open-label, uncontrolled, monocenter, phase IV study. The aim of this study is to detect AEs or SAEs with a relative frequency of at least 11.5% in LVAD patients with iron deficiency anemia treated with oral ferric…
- Trial name
- ORION-LVAD-1 (NCT03774615)
- Testing
- Ferric maltol 30 mg (Feraccru®)
- Where
- Germany
- Volunteers
- 11 people
- Sponsor
- Hannover Medical School
Adverse Drug Reactions
The Influence of CYP2C19 Polymorphisms on the Safety and Efficacy of Voriconazole
Voriconazole is a drug used to treat invasive fungal infections. The amount of voriconazole in a person's blood helps to determine how effectively it treats an infection, and how safe it is.
- Trial name
- NCT04547335
- Testing
- Voriconazole
- Where
- Turkey (Türkiye)
- Volunteers
- 34 people
- Sponsor
- Dokuz Eylul University
Heart Failure, Coronary Artery Disease
COVID-19 Testing in Underserved and Vulnerable Populations
As part of National Institutes of Health Rapid Acceleration of Diagnostics-Underserved Populations (RADx-UP) program, the goal of the RADxUP study is to develop, test, and evaluate a rapid, scalable capacity building project to…
- Conditions
- Heart Failure, Coronary Artery Disease, Cancer, Chronic Kidney Diseases
- Trial name
- NCT05315908
- Testing
- Community outreach method
- Where
- United States
- Volunteers
- 9,120 people
- Sponsor
- Jesse Nodora
Sepsis
Immunothrombosis With Septic Shock Undergoing Renal Replacement Therapy With the OXIRIS Membrane
Sepsis remains a global scourge. Before the SARS-CoV-2 pandemic, the World Health Organization estimated approximately 49 million cases annually, resulting in 11 million deaths.
- Trial name
- PLAQSIRIS (NCT06440317)
- Testing
- Hemofiltration membranes (the oXiris membrane® and the HF1400® membrane)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Bordeaux
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.